信迪利单抗致晚期鳞状细胞肺癌患者致死性中毒性表皮坏死松解症1例 - betway必威登陆网址

国际肿瘤学杂志››2022,Vol. 49››Issue (6): 380-382.doi:10.3760/cma.j.cn371439-20211115-00073

• 病例报道 •上一篇下一篇

信迪利单抗致晚期鳞状细胞肺癌患者致死性中毒性表皮坏死松解症1例

王永洪¹, 何弢¹(), 李星¹, 罗启余¹, 王乔羽²

¹成都医学院第二附属医院核工业四一六医院胸外科,成都 610000
²成都医学院第二附属医院核工业四一六医院药学部,成都 610000

收稿日期:2021-11-15修回日期:2022-03-29出版日期:2022-06-08发布日期:2022-06-30
通讯作者:何弢 E-mail:178961830@qq.com

Received:2021-11-15Revised:2022-03-29Online:2022-06-08Published:2022-06-30

摘要/Abstract

摘要：

中毒性表皮坏死松解症（TEN）是免疫治疗中一种罕见不良反应,其进展快、死亡率高。本文报道1例晚期鳞状细胞肺癌在使用信迪利单抗免疫治疗后出现TEN致死亡的病例。TEN需引起临床医生广泛关注,做到早期诊断、规范治疗。

王永洪, 何弢, 李星, 罗启余, 王乔羽. 信迪利单抗致晚期鳞状细胞肺癌患者致死性中毒性表皮坏死松解症1例[J]. 国际肿瘤学杂志, 2022, 49(6): 380-382.

图/表2

参考文献17

[1]	Estrella-Alonso A, Aramburu JA, González-Ruiz MY, et al. Toxic epidermal necrolysis: a paradigm of critical illness[J]. Rev Bras Ter Intensiva, 2017, 29(4): 499-508. DOI: 10.5935/0103-507X.20170075. doi:10.5935/0103-507X.20170075
[2]	Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016[J]. J Plast Reconstr Aesthet Surg, 2016, 69(6): e119-e153. DOI: 10.1016/j.bjps.2016.01.034. doi:10.1016/j.bjps.2016.01.034pmid:27287213
[3]	Wang YH, Chen CB, Tassaneeyakul W, et al. The medication risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in Asians: the major drug causality and comparison with the US FDA label[J]. Clin Pharmacol Ther, 2019, 105(1): 112-120. DOI: 10.1002/cpt.1071. doi:10.1002/cpt.1071
[4]	Trent J, Halem M, French LE, et al. Toxic epidermal necrolysis and intravenous immunoglobulin: a review[J]. Semin Cutan Med Surg, 2006, 25(2): 91-93. DOI: 10.1016/j.sder.2006.04.004. doi:10.1016/j.sder.2006.04.004
[5]	胡雪, 曹雪, 宋燕青, 等. 头孢菌素类药物致史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的文献分析[J]. 中国医院药学杂志, 2021, 41(8): 840-845. DOI: 10.13286/j.1001-5213.2021.08.14. doi:10.13286/j.1001-5213.2021.08.14
[6]	徐利君, 李星霞. 左氧氟沙星疑致中毒性表皮坏死松解型药疹1例[J]. 中国药物应用与监测, 2015, 12(4): 258-260.
[7]	陈魁霞, 潘丹, 李立, 等. 左氧氟沙星注射液致中毒性表皮坏死松解症[J]. 药物不良反应杂志, 2020, 22(9): 537-538. DOI: 10.3760/cma.j.cn114015-20190904-00734. doi:10.3760/cma.j.cn114015-20190904-00734
[8]	Cai ZR, Lecours J, Adam JP, et al. Toxic epidermal necrolysis associated with pembrolizumab[J]. J Oncol Pharm Pract, 2020, 26(5): 1259-1265. DOI: 10.1177/1078155219890659. doi:10.1177/1078155219890659
[9]	何琳, 陈适, 夏陈英, 等. 1例卡瑞利珠单抗致中毒性表皮坏死松解症并文献复习[J]. 中南药学, 2021, 19(8): 1751-1754. DOI: 10.7539/j.issn.1672-2981.2021.08.049. doi:10.7539/j.issn.1672-2981.2021.08.049
[10]	邓爱清, 殷晓芹, 朱秋燕, 等. 替雷利珠单抗相关中毒性表皮坏死松解症1例[J]. 中国医院药学杂志, 2021, 41(19): 2039-2040. DOI: 10.13286/j.1001-5213.2021.19.22. doi:10.13286/j.1001-5213.2021.19.22
[11]	李欣, 刘玉, 韩建文. 中毒性表皮坏死松解症17例临床分析[J]. 临床皮肤科杂志, 2020, 49(8): 465-467. DOI: 10.16761/j.cnki.1000-4963.2020.08.006. doi:10.16761/j.cnki.1000-4963.2020.08.006
[12]	Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis[J]. Clin Pharmacol Ther, 2010, 88(1): 60-68. DOI: 10.1038/clpt.2009.252. doi:10.1038/clpt.2009.252pmid:20375998
[13]	Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000, 115(2): 149-153. DOI: 10.1046/j.1523-1747.2000.00061.x. doi:10.1046/j.1523-1747.2000.00061.xpmid:10951229
[14]	Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges[J]. J Hematol Oncol, 2018, 11(1): 39. DOI: 10.1186/s13045-018-0582-8. doi:10.1186/s13045-018-0582-8
[15]	Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3): 345-361. DOI: 10.1007/s40257-017-0336-3. doi:10.1007/s40257-017-0336-3
[16]	Choonhakarn C, Limpawattana P, Chaowattanapanit S. Clinical profiles and treatment outcomes of systemic corticosteroids for toxic epidermal necrolysis: a retrospective study[J]. J Dermatol, 2016, 43(2): 156-161. DOI: 10.1111/1346-8138.13040. doi:10.1111/1346-8138.13040
[17]	Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012. doi:10.6004/jnccn.2020.0012

相关文章15

编辑推荐

Metrics

本文评价